KOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved efficacy.

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Incidence, predictors and outcomes of cardiovascular events in patients with chronic lymphocytic leukemia. Summary of NMA results: PFS of zanubrutinib compared with frontline treatments for TN CLL.

Thermal noise in magnetic tunnel junctions, usually suppressed, now serves as a tunable source of randomness for Bayesian ...